Related Experiment Videos

Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children

W J King1, N E MacDonald, G Wells

  • 1Department of Pediatrics, Children's Hospital Eastern Ontario, University of Ottawa, Canada.

The Journal of Pediatrics
|February 1, 1996
PubMed

Insights

This study found that total antibody response is a good indicator of functional antibody in children over 18 months old after meningococcal C vaccination. Younger children may need revaccination.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Neisseria meningitidis serogroup C poses a significant public health risk.
  • Quadrivalent meningococcal polysaccharide vaccines are used for prevention.
  • Assessing vaccine effectiveness requires understanding antibody responses.

Purpose of the Study:

  • To evaluate total and functional antibody responses to a quadrivalent meningococcal polysaccharide vaccine.
  • To determine the correlation between total and functional antibodies in different age groups.
  • To inform vaccination strategies for Neisseria meningitidis serogroup C.

Main Methods:

  • Prospective study design with pre- and post-vaccination assessments.
  • Inclusion of participants aged 0.5 to 19.9 years undergoing a public health immunization campaign.
  • Measurement of total antibodies via enzyme-linked immunosorbent assay and functional antibodies via bactericidal assay.

Main Results:

  • Significant increase in total capsular polysaccharide antibody one month post-vaccination across all age groups.
  • Significant rise in bactericidal antibody, correlating with total antibody, observed in children aged 18 months and older.
  • Bactericidal antibody titers were maintained at 1 year, while capsular polysaccharide antibody levels decreased substantially in children under 5 years.

Conclusions:

  • Total capsular polysaccharide antibody concentration can serve as a surrogate for bactericidal antibody in children 18 months and older.
  • Consideration for revaccination is recommended for children vaccinated before 18 months if ongoing risk exists.
  • Further vaccine efficacy trials are necessary to establish serologic correlates of protection due to differing antibody dynamics.
Abstract

Related Concept Videos